Craft

iBio

Stock Price

$0.3

2023-09-27

Market Capitalization

$6.6 M

2023-09-27

Revenue

$2.4 M

FY, 2022

iBio Summary

Company Summary

Overview
iBio is a biotechnology company and biologics contract development and manufacturing organization (CDMO). It develops products to treat fibrotic diseases, cancers, and infectious diseases. iBio's platforms and programs include CDMO services using its FastPharming technologies and glycaneering services; the development of therapeutics and vaccines, for which iBio conducts preclinical and clinical trials, and the production of proteins for research and further manufacturing use in 3D-bioprinting and other applications.
Type
Public
Status
Active
Founded
2008
HQ
Bryan, TX, US | view all locations
Website
http://ibioinc.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Thomas F. Isett

    Thomas F. Isett, Chief Executive Officer & Chairman of the Board

  • Martin B. Brenner

    Martin B. Brenner, Chief Scientific Officer

  • Lisa Middlebrook

    Lisa Middlebrook, Chief Human Resources Officer

  • Gary Sender

Operating MetricsView all

Patents Issued

67

FY, 2016

Patents Pending

19

FY, 2016

LocationsView all

1 location detected

  • Bryan, TX HQ

    United States

    8800 HSC Pkwy

iBio Financials

Summary Financials

Net income (Q3, 2023)
($7.3M)
Cash (Q3, 2023)
$6.6M
EBIT (Q3, 2023)
($6.2M)
Enterprise value
$14.2M

Footer menu